- Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
- Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
- Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib
As of last trade
Pharming Group NV (PHG:FRA) traded at 11.50, -7.26% below its 52-week high of 12.40, set on Dec 01, 2022.
6.00Jun 17 202212.40Dec 01 2022
Markit short selling activity
Data delayed at least 15 minutes, as of Dec 06 2022 08:15 GMT.